Hormone-receptor-positive high-grade serous or endometrioid ovarian carcinoma.Chemotherapy (paclitaxel and carboplatin) and Bevacizumab plus Exemestane (Aromasin) (Aromatase inhibitor) or placebo.Randomised, quadruple-blind. This evidence concerns the gene CYP19A1 and ovarian endometrioid carcinoma.